Concordance between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology between Three Independent Assay Platforms

JD Doecke; A Rembach; VL Villemagne; S Varghese; S Rainey-Smith; S Sarros; LA Evered; CJ Fowler; KK Pertile; RL Rumble; B Trounson; K Taddei; SM Laws; SL Macaulay; AI Bush; KA Ellis; R Martins; D Ames; B Silbert; H Vanderstichele; CL Masters; DG Darby; QX Li; S Collins

Journal article

Concordance between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology between Three Independent Assay Platforms

JD Doecke, A Rembach, VL Villemagne, S Varghese, S Rainey-Smith, S Sarros, LA Evered, CJ Fowler, KK Pertile, RL Rumble, B Trounson, K Taddei, SM Laws, SL Macaulay, AI Bush, KA Ellis, R Martins, D Ames, B Silbert, H Vanderstichele Show all

Journal of Alzheimer S Disease | IOS PRESS | Published : 2018

DOI: 10.3233/JAD-170128

Download PDF

Abstract

Background: To enhance the accuracy of clinical diagnosis for Alzheimer's disease (AD), pre-mortem biomarkers have become increasingly important for diagnosis and for participant recruitment in disease-specific treatment trials. Cerebrospinal fluid (CSF) biomarkers provide a low-cost alternative to positron emission tomography (PET) imaging for in vivo quantification of different AD pathological hallmarks in the brains of affected subjects; however, consensus around the best platform, most informative biomarker and correlations across different methodologies are controversial. Objective: Assessing levels of Aβ-amyloid and tau species determined using three different versions of immunoassays,..

View full abstract

University of Melbourne Researchers

Victor Villemagne Author

Lis Evered Author

Ashley Bush Author

Kathryn Ellis Author

Related Projects (2)

MOLECULAR IMAGING OF NEURODEGENERATION

This research proposal outlines studies aimed at identifying specific biomarkers of neurodegeneration. Given the complexity and clinical ove..

TACKLING KEY EPIDEMIOLOGICAL AND BASIC SCIENTIFIC RESEARCH ISSUES IN PRION DISEASES.

Proposed Practitioner Fellowship research will simultaneously include epidemiological and basic scientific projects, emphasising human prion..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

The Florey Institute of Neuroscience and Mental Health acknowledges funding support from the Victorian government's Operational Infrastructure Support program. Alzheimer's Australia (Victoria and Western Australia) assisted with promotion of the study. SC is supported in part by a NHMRC Practitioner Fellowship (#APP1105784). VLV is supported in part by a NHMRC Research Fellowship (#APP1046471). This study would like to acknowledge the generous participation of the AIBL participants, who kindly provided their time and resources so that this research was possible.Core funding for the study was provided by the Science and Industry Endowment Fund (http://www.sief.org.au) and CSIRO, which was supplemented by in kind contributions from the study partners (see http://www.aibl.csiro.au). The research was also supported by the National Health and Medical Research Council (NHMRC) via the Dementia Collaborative Research Centres program (DCRC).